Trials / Recruiting
RecruitingNCT03681275
Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
A Clinical Trial of JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tofacitinib 10 MG [Xeljanz] | administered twice daily for two days |
| DRUG | Placebo to match Tofacitinib | administered twice daily for two days |
Timeline
- Start date
- 2019-09-03
- Primary completion
- 2025-11-30
- Completion
- 2026-11-30
- First posted
- 2018-09-24
- Last updated
- 2024-11-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03681275. Inclusion in this directory is not an endorsement.